Patients with breast cancer and very low mammographic breast density have a poorer prognosis.
Very low mammographic breast density is associated with higher tumor grade and predicted worse survival, according to a study published in the journal European Radiology.
Researchers from Finland examined the prognostic value of mammographic breast density (MBD) and any relationship with established prognostic factors in patients with invasive breast cancer.
The study included 270 women with breast cancer. The researchers classified MBD according to percentile density: <5%, 5%–10%, 10%–25%, 25%–50%, 50%–75%, and >75%. The cases were also categorized into very low density (VLD; <10%), low density (LOD; <25%) and mixed density (MID; >25%).
The researchers found that MBD was inversely associated with tumor grade. Patients with LOD breasts had worse prognoses compared to those with MID breasts.
The strongest significance was seen among patients with VLD breasts compared to the remaining patients. No other mammographic feature was prognostically significant.
"It is difficult to detect small tumors when screening dense breasts, and this results in a higher occurrence of clinically detectable interval cancers,” Professor Ritva Vanninen, said in a release. “In the U.S., it is nowadays mandatory to let patients know if they have dense breast tissue. This allows them to choose whether they wish to have further tests, for example a screening ultrasound."
Mammography Study: Can Stand-Alone AI Enhance Detection of Interval Breast Cancer?
August 28th 2024Identifying over 23 percent of interval breast cancers with a 96 percent sensitivity in mammography interpretation, an emerging AI software also facilitated correct localization in over 75 percent of cases involving interval breast cancer, according to new research.
Can AI Facilitate Effective Triage for Supplemental Breast MRI After Negative Mammography Screening?
July 10th 2024The AISmartDensity software facilitated a cancer detection rate (CDR) with breast MRI that was nearly four times higher than the CDR previously reported in trials involving traditional breast density assessment.